Pneumococcal vaccine does not appear to protect against pneumonia

Jan 05, 2009

Commonly used pneumococcal polysaccharide vaccines do not appear to be effective for preventing pneumonia, found a study by a team of researchers from Switzerland and the United Kingdom.

In many industrialized countries, polysaccharide pneumococcal vaccines (PPVs) are currently recommended to help prevent pneumococcal disease in people aged 65 and over and for younger people with increased risk due to conditions like HIV. Studies have shown conflicting results regarding the efficacy of PPV.

The study, a systematic review and meta-analysis, looked at 22 clinical trials, reviews and meta-analyses and more than 100,000 participants from countries in North America as well as India, Africa, Latin America and the Caribbean. Unlike other similar studies the authors examined the reasons why different clinical trials produced different results. They found that the quality of the studies substantially affected the results. When only high quality trials were included, there was no evidence that PPVs could prevent pneumonia. The study adds to the ongoing debate around effectiveness of the vaccine.

"Policy makers may therefore wish to reconsider their current recommendations for PPV, especially where routine pneumococcal conjugate immunization has been introduced," conclude Dr. Matthias Egger from the University of Bern, Switzerland and coauthors.

However, in a related commentary www.cmaj.ca/press/pg18.pdf, Dr. Ross Andrews and coauthor from the Menzies School of Health Research, Darwin, Australia state that the researchers' conclusions exceed the evidence presented. They caution that there should be no change in vaccine policy in countries that recommend PPV to prevent invasive pneumococcal disease.

Paper: www.cmaj.ca/press/pg48.pdf

Source: Canadian Medical Association Journal

Explore further: Generic form of nexium approved

add to favorites email to friend print save as pdf

Related Stories

Health checks will be seated by Sharp

Dec 08, 2014

(Phys.org) —Sharp unveiled a news-making prototype of a sensor earlier this month at Semicon Japan 2014, which took place from Dec 3 to 5. As its title suggests, Sharp's "Blood Vessel Aging Degree Sensor" ...

More safety on thermal drying plants of sewage sludge

Dec 23, 2014

Researchers from the Madariaga Lab at the Universidad Politécnica de Madrid have carried out a series of trials to study the explosiveness of sludge on thermal drying plants of sewage sludge. The obtained ...

Recommended for you

Generic form of nexium approved

6 hours ago

(HealthDay)—The first generic version of the heartburn drug Nexium (esomeprazole) has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.